Thousands of men suffering from prostate cancer are being systematically denied access to a groundbreaking 'quality of life-preserving' treatment by the National Health Service. Focal therapy, a non-invasive medical procedure that precisely targets cancerous cells while meticulously avoiding damage to surrounding healthy tissue, was first introduced to the United Kingdom in 2006. This innovative treatment offers a significantly reduced risk of debilitating side effects, including incontinence and erectile dysfunction, which can affect up to 20 percent of men undergoing conventional cancer treatments like radiotherapy.
Superior Outcomes and Cost Efficiency
Focal therapy is not only more effective in preserving patients' quality of life but is also substantially cheaper than alternative treatments. Patients typically undergo the procedure and are discharged from hospital within a single day, with a markedly lower likelihood of requiring extensive follow-up care. Despite these clear advantages and the potential benefit for approximately 15,000 men annually, the treatment remains exceptionally rare within the NHS framework. Only a handful of specialist centres, predominantly located in London, currently perform focal therapy, as medical professionals warn that the vast majority of patients are not even informed about this viable option and consequently face life-altering side effects from more invasive procedures.
A Stark Treatment Disparity
While around 60,000 men are diagnosed with prostate cancer each year in the UK, a mere 600 to 700 are estimated to be offered focal therapy through the NHS. In stark contrast, the treatment is widely available in the private healthcare sector for an average cost of £16,000. Notably, former Prime Minister David Cameron opted for private focal therapy after his prostate cancer diagnosis. His diagnosis followed his wife Samantha's urging to undergo a prostate-specific antigen (PSA) test after she listened to a radio interview discussing symptoms.
Clinical Evidence and Professional Advocacy
According to a comprehensive study published by Imperial College London, focal therapy is just as effective as traditional surgery. The research demonstrated that only one in twenty patients experienced side effects such as incontinence, compared to six in ten who underwent conventional surgical procedures. Professor Hashim Ahmed, Chair of Urology at Imperial College London, who played a pivotal role in introducing focal therapy to the UK, stated emphatically: 'Men with prostate cancer have a right to know that focal therapy is open to them as an alternative option to surgery, radiotherapy, and active surveillance, but that is not the case.'
Professor Ahmed expressed profound frustration in an interview with The Times, noting: 'It's been 20 years since I worked with Professor Mark Emberton on introducing focal therapy in the UK and, in many ways, we're no further along, even though the technology has moved on considerably.' He elaborated on the systemic failure, adding: 'We have seen cases where patients attend an NHS cancer centre, are told of their diagnosis and are offered surgery or radiotherapy as the main options, with focal therapy not mentioned at all. Those patients then go away, research it themselves, come back and ask, 'What about focal therapy?' and are told, 'No, it's not proven, we don't recommend it.' Some patients end up absolutely fighting for it, insisting they want focal therapy, and only then are they finally referred.' He has urgently called for the NHS to implement this treatment at more hospitals across the nation.
Technological Advancements and Limited Access
There are three principal forms of focal therapy: High-Intensity Focused Ultrasound (HIFU), which uses ultrasound waves to generate heat and destroy cancer cells; irreversible electroporation, which targets tumours with electrical pulses that kill cells; and cryotherapy, which employs extreme cold to freeze and eradicate cancer cells using a technology called NanoKnife. Professor Ahmed hailed the introduction of NanoKnife as 'genuinely game-changing.' However, access remains severely restricted, with Lord Cameron being one of only 175 patients to receive NanoKnife treatment across the entire country last year.
The NHS has defended its position, claiming that 'current guidance notes limited evidence on the effectiveness of cryotherapy and high-intensity focused ultrasound.' This stance persists despite mounting clinical evidence and patient demand, leaving thousands of men without access to a treatment that could preserve their dignity and quality of life.
